Department of Radiation Oncology Posters

Follow

• 

  Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer

  Frank J. Arturi; Nilanjan Haldar; Shray Jain; Gia Nguyen; Jessie Dinome; Firas Mourtada; and Lydia J. Wilson, PhD

  Introduction

  • Radiopharmaceutical Therapy (RPT) uses radioactive agents to target cancer at the cellular level
  • Lu-177 targeting prostate-specific membrane antigen (PSMA), known as 177Lu- PSMA-617, can be used to treat metastatic, castration-resistant prostate cancer (mCRPC)
  • 177Lu-PSMA-617 treatments use a standard dose and treatment regimen for all patients
  • Patients exhibit different side effects and tumor response during treatment

• 

  Calibration of a Novel Microdosimetry System for In Vitro Applications of Actinide Radiopharmaceuticals

  Lydia J. Wilson, Brian Miller, George Tabatadze, and Firas Mourtada

  Background

  • Alpha-emitting radionuclides show promise for targeted radiopharmaceutical therapy (TRT).
  • High linear energy transfer and short range cause highly localized DNA damage for effective cancer cell eradication.
  • However, distributions of radioactivity and absorbed dose on the cellular scale remain elusive.
  • Progress toward understanding α-TRT radiobiologic response, evaluating novel α-TRT drug efficacy, and optimizing administration for personalized treatments will require knowledge of radioactivity and absorbed dose distributions.
  • A novel real-time α camera, the ionizing radiation quantum imaging detector (iQID), has successfully mapped the microdistribution of α-emitting radionuclides in mouse and human tissues [1].

• 

  Results of a Prospective Trial to Evaluate Novel Lung Function Imaging for Lung Cancer Surgery

  Lydia J. Wilson, PhD; Richard Castillo, PhD; Edward Castillo, PhD; Bernard Jones, PhD; Moyed Miften, PhD; Lindsey Olsen, PhD; Vikas Aragam, PhD; Robert A. Meguid, MD, MPH; Crystal J. Erickson, MD; Amanda Young, MSN; Matthew Blum, MD; Tyler Grenda, MD; Julie Barta, MD; Benjamin Leiby, PhD; Timothy Waxweiler, MD; Brian Kavanagh, MD, MPH; John D. Mitchell, MD; and Yevgeniy Vinogradskiy, PhD

  Background

  • Surgery is the primary form of definitive treatment for early-stage lung cancer.
  • Poor lung function before surgery places patients at high risk of pulmonary complications after resection.
  • Surgeons evaluate patient fitness for surgery using pulmonary function tests (PFTs) to calculate the predicted postoperative PFT (ppoPFT).
  • Conventional ppoPFT calculations assume homogeneous lung function, which can be inaccurate.
  • 4DCT-ventilation is a novel lung function imaging modality developed in radiation oncology that uses 4DCT data to calculate high-resolution ventilation maps.

• 

  Inducing Accelerated Lung Toxicity in Mice Using a Partial Arc SBRT Technique

  Andrew Gerry, Charita Kunta, Noelle Francois, Tiziana DeAngelis, Anuradha Shastri, Nicole Simone, and Reza Taleei

  Background

  • Radiation-induced pulmonary fibrosis (RIPF) is a frequent outcome of thoracic radiation therapy, constraining safe tumor radiation dosage. Various animal models, such as mice, rats, and pigs, have been devised to study RIPF
  • Current methods for inducing lung fibrosis in mice involve whole lung irradiation with doses between 2-20 Gy. These methods used fixed anterior and posterior (AP/PA) x-ray beams at 0º and 180º with analysis typically commencing 24 to 52 weeks post-radiation
  • Current methods are unrepresentative of modern radiation therapy techniques and are limited by the associated long latency of RIPF